日本系统性慢性活动性EB病毒感染患者造血干细胞移植的注册数据分析
利用日本移植注册数据库分析102例接受异基因造血干细胞移植的系统性慢性活动性EB病毒感染患者,3年总生存率为72.5%,90例可评估病毒载量者中56例(62.2%)达病毒学完全缓解;多因素分析显示青少年和青年组、成人组、疾病活动、可溶性IL-2受体升高及未含放疗的预处理方案与较差生存独立相关。
要点
- 102例患者移植时中位年龄21岁,3年总生存率72.5%。
- 90例可评估者中56例(62.2%)达病毒学完全缓解。
- 青少年和青年组及成人组、高sIL-2R、疾病活动、未含放疗预处理与较差生存独立相关。
核心结论
- 异基因造血干细胞移植是系统性慢性活动性EB病毒感染的唯一治愈性疗法,但高危患者尤其是可溶性IL-2受体高水平者的治疗策略仍需改进。
研究设计与样本
- 利用日本移植注册数据库「移植注册统一管理计划」对102例接受异基因造血干细胞移植的系统性慢性活动性EB病毒感染患者进行注册数据分析。
主要发现
- 移植时中位年龄21岁,3年总生存率为72.5%。
- 90例移植后评估病毒载量的患者中,56例(62.2%)达到病毒学完全缓解,定义为疾病活动完全消退且外周血EBV-DNA显著下降。
- 多因素Cox比例风险模型显示,青少年和青年组(年龄15-39岁)成人组(年龄≥40岁)与较差总生存相关,风险比分别为10.87(95%CI:1.98-59.56,p=.006)和15.93(95%CI:2.45-103.8,p=.004)。
- 疾病活动(HR 5.74)、移植时可溶性IL-2受体升高(≥中位数691 U/mL,HR 6.93)及未含放疗的预处理方案(HR 3.53)亦与较差生存独立相关。
- 放疗剂量中79%低于6 Gy;无论有无噬血细胞性淋巴组织细胞增生症,可溶性IL-2受体高水平组(≥2000 U/mL)预后更差。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The effects of allogeneic hematopoietic stem cell transplantation (allo-HSCT) on systemic chronic active Epstein-Barr virus infection (sCAEBV) are yet to be analyzed in a large number of patients. Using the Japanese registry database, Transplant Registry Unification Management Program, we investigated the outcomes of 102 sCAEBV patients who underwent allo-HSCT. The median age at HSCT was 21 years, and the three-year overall survival (3-year OS) rate was 72.5%. Of the 90 patients whose viral load after allo-HSCT was evaluated, 56 (62.2%) achieved a virological complete response, defined by the complete resolution of disease activity with a significant decrease in EBV-DNA in peripheral blood. The multivariate Cox proportional hazard model indicated that advanced age, in adolescents and young adults (AYA) (age, 15-39) and adults (age, ≥40 years) was a risk factor of poor OS. The hazard ratios (HRs) of the AYA and adult groups were 10.87 (95% confidence interval [CI]: 1.98-59.56, p = .006) and 15.93 (95% CI: 2.45-103.8, p = .004), respectively. Disease activity (HR 5.74), elevated soluble IL-2 receptor (sIL-2R) (≥ median, 691 U/mL) at HSCT (HR 6.93), and conditioning without radiotherapy (HR 3.53) were also independently associated with poor survival. Notably, 79% of radiotherapy doses were less than 6 Gy. Regardless of the presence of hemophagocytic lymphohistiocytosis, the group with a high sIL-2R level (≥2000 U/mL) showed a poorer prognosis. Although allo-HSCT is the only curative therapy for sCAEBV, treatment strategies need to be improved for high-risk patients, especially those with high levels of sIL-2R.
引用
- Yamamoto M, Sato M, Onishi Y, et al. Registry data analysis of hematopoietic stem cell transplantation on systemic chronic active Epstein-Barr virus infection patients in Japan. Am J Hematol. 2022. PMID: 35312194. doi:10.1002/ajh.26544
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。